Home › Research › Treatments
Appropriate use recommendations of the Spanish Society of Neurology’s Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease
Raquel Sánchez‐Valle, Daniel Andres Alcolea, Guillermo Amer Ferrer, Mircea Balasa, Ignacio Casado Naranjo, Juan Fortea, Albert Lladó, Alberto Lleó et al.. Neurología (English Edition), 2026-05-01
Topic: Amyloid, tau and blood-test diagnosis
The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of AD, but is not free of challenges. The participating experts showed a high level of consensus on basic clinical and practical considerations, with the requirements of prescribing centres and criteria for treatment suspension being the areas that generated the most debate. Participants noted concerns about equity of access and implementation into current care, particularly if insufficient resources are allocated to this implementation. This document will require updates in line with new knowledge and/or approval of new drugs in this class.
Key findings
- The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of AD, but is not free of challenges.
- The participating experts showed a high level of consensus on basic clinical and practical considerations, with the requirements of prescribing centres and criteria for treatment suspension being the areas that generated the most debate.
- Participants noted concerns about equity of access and implementation into current care, particularly if insufficient resources are allocated to this implementation.
- This document will require updates in line with new knowledge and/or approval of new drugs in this class.
Why it matters
This consensus document from the Spanish Society of Neurology's study group addresses practical considerations for using anti-amyloid antibodies, with prescribing centre requirements and criteria for stopping treatment generating the most debate. It notes concerns about equity of access and implementation into current care if insufficient resources are allocated, and will need updating as new knowledge or drugs emerge.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 31 of the 96 points we could judge it on, which is 32 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurología (English Edition)) |
| Journal's citation record | 0 / 4 | Neurología (English Edition): journal h-index 47 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author H. Vico Bondía holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Universitat de Barcelona: institution h-index 1,049 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 19 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42202980) |
| Free to read | 2 / 2 | Free to read |
| Points | 31 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 31 of the 96 points we could judge it on is 32 out of 100. |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.nrleng.2026.502075
- PubMed: 42202980
- Original source →
- Free full text: Neurología (English Edition) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Sánchez‐Valle, R., Alcolea, D. A., Ferrer, G. A., Balasa, M., Naranjo, I. C., Fortea, J., et al. (2026). Appropriate use recommendations of the Spanish Society of Neurology’s Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease. Neurología (English Edition). https://doi.org/10.1016/j.nrleng.2026.502075
Vancouver
Sánchez‐Valle R, Alcolea DA, Ferrer GA, Balasa M, Naranjo IC, Fortea J, et al. Appropriate use recommendations of the Spanish Society of Neurology’s Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease. Neurología (English Edition). 2026. doi:10.1016/j.nrleng.2026.502075. PMID: 42202980.
BibTeX
@article{sanchezvalle2026-42202980,
author = {Sánchez‐Valle, Raquel and Alcolea, Daniel Andres and Ferrer, Guillermo Amer and Balasa, Mircea and Naranjo, Ignacio Casado and Fortea, Juan and Lladó, Albert and Lleó, Alberto and others},
title = {{Appropriate use recommendations of the Spanish Society of Neurology’s Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease}},
journal = {Neurología (English Edition)},
year = {2026},
doi = {10.1016/j.nrleng.2026.502075},
pmid = {42202980},
url = {https://doi.org/10.1016/j.nrleng.2026.502075}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.